Details for Patent: 9,649,306
Which drugs does patent 9,649,306 protect, and when does it expire?
Patent 9,649,306 protects ROZLYTREK and is included in one NDA.
This patent has thirty-one patent family members in seventeen countries.
Summary for Patent: 9,649,306
| Title: | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
| Abstract: | The present invention relates to a process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide. Novel solid forms of this compound, their utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing them are also object of the present invention. |
| Inventor(s): | Natale Alvaro BARBUGIAN, Romualdo Forino, Tiziano Fumagalli, Paolo Orsini |
| Assignee: | Nerviano Medical Sciences SRL |
| Application Number: | US15/172,478 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 9,649,306
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-001 | Aug 15, 2019 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION | ⤷ Start Trial | ||||
| Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-001 | Aug 15, 2019 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER | ⤷ Start Trial | ||||
| Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-002 | Aug 15, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION | ⤷ Start Trial | ||||
| Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-002 | Aug 15, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,649,306
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 12169139 | May 23, 2012 | |
International Family Members for US Patent 9,649,306
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 091138 | ⤷ Start Trial | |||
| Australia | 2013265288 | ⤷ Start Trial | |||
| Australia | 2018201037 | ⤷ Start Trial | |||
| Brazil | 112014028841 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
